National Vaccine Injury Compensation Program: Revised Amount of the Average Cost of a Health Insurance Policy, 69230 [2015-28436]
Download as PDF
<![CDATA[
69230
Federal Register / Vol. 80, No. 216 / Monday, November 9, 2015 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Dated: November 3, 2015.
James Macrae,
Acting Administrator.
[FR Doc. 2015–28436 Filed 11–6–15; 8:45 am]
BILLING CODE 4165–15–P
srobinson on DSK5SPTVN1PROD with NOTICES
National Vaccine Injury Compensation
Program: Revised Amount of the
Average Cost of a Health Insurance
Policy
The Health Resources and Services
Administration (HRSA) is publishing an
updated monetary amount of the
average cost of a health insurance policy
as it relates to the National Vaccine
Injury Compensation Program (VICP).
Section 100.2 of the VICP’s
implementing regulation (42 CFR part
100) states that the revised amount of
the average cost of a health insurance
policy, as determined by the Secretary
of Health and Human Services, is
effective upon its delivery to the United
States Court of Federal Claims (the
Court), and will be published
periodically in a notice in the Federal
Register. This figure is calculated using
the most recent Medical Expenditure
Panel Survey-Insurance Component
(MEPS–IC) data available as the baseline
for the average monthly cost of a health
insurance policy. This baseline is
adjusted by the annual percentage
increase/decrease obtained from the
most recent annual Kaiser Family
Foundation and Health Research and
Educational Trust (KFF/HRET)
Employer Health Benefits survey or
other authoritative source that may be
more accurate or appropriate.
In 2015, MEPS–IC, available at
www.meps.ahrq.gov, published the
annual 2014 average total single
premium amount per enrolled employee
at private-sector establishments that
provide health insurance. The figure
published was $5,832. This figure is
divided by 12-months to determine the
cost per month of $486.00. The $486.00
shall be increased or decreased by the
percentage change reported by the most
recent KFF/HRET, available at
www.kff.org. The percentage increase
from 2014 to 2015 was published at 4
percent. By adding this percentage
increase, the calculated average monthly
cost of a health insurance policy in 2015
is $505.44.
Therefore, the Secretary of Health and
Human Services announces that the
revised average cost of a health
insurance policy under the VICP is
$505.44 per month. In accordance with
§ 100.2, the revised amount was
effective upon its delivery by the
Secretary to the Court. Such notice was
delivered to the Court on October 23,
2015.
VerDate Sep<11>2014
19:52 Nov 06, 2015
Jkt 238001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Anil Potti, M.D., Duke University
School of Medicine: Based on the
reports of investigations conducted by
Duke University School of Medicine
(Duke) and additional analysis
conducted by ORI in its oversight
review, ORI found that Dr. Anil Potti,
former Associate Professor of Medicine,
Duke, engaged in research misconduct
in research supported by National Heart,
Lung, and Blood Institute (NHLBI),
National Institutes of Health (NIH),
grant R01 HL072208 and National
Cancer Institute (NCI), NIH, grants R01
CA136530, R01 CA131049, K12
CA100639, R01 CA106520, and U54
CA112952.
ORI found that Respondent engaged
in research misconduct by including
false research data in the following
published papers, submitted
manuscript, grant application, and the
research record as specified in 1–3
below. Specifically, ORI found that:
1. Respondent stated in grant
application 1 R01 CA136530–01A1 that
6 out of 33 patients responded
positively to dasatinib when only 4
patients were enrolled and none
responded and that the 4 CT scans
presented in Figure 14 were from the
lung cancer study when they were not.
2. Respondent altered data sets to
improve the accuracy of predictors for
response to treatments in a submitted
paper and in the research record by:
• Reversing the responder status of 24
out of 133 subjects for the adriamycin
predictor in a manuscript submitted to
Clinical Cancer Research
• switching the cancer recurrence
phenotype for 46 out of 89 samples to
validate the LMS predictor in a file
provided to a colleague in 2008
• changing IC–50 and R-code values
for the cisplatin predictor in a data set
provided to NCI in 2010
3. Respondent reported predictors
and/or their validation by disregarding
SUMMARY:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
accepted scientific methodology so that
false data were reported in the
following:
• Blood 107:1391–1396, 2006:
Describing a predictor for thrombotic
phenotypes
• New England Journal of Medicine
355:570–580, 2006: Describing a
predictor of lung cancer relapse
• Nature Medicine 12:1294–1300,
2006: Describing a predictor for the
response to the chemotherapeutic drugs
topectan and docetaxol
• Journal of Clinical Oncology
25:4350–4357, 2007: Describing a
predictor for the response to the
chemotherapeutic drug cisplatin
• Lancet Oncology 8:1071–1078,
2007: Describing a predictor for the
response to the combination of the
chemotherapeutic drugs flurouracil,
epirubicin, and cyclophosphamide or
docetaxol, epirubicin, and docetaxol
• Journal of the American Medical
Association 299:1574–1587, 2008:
Describing a predictor for breast cancer
relapse
• Public Library Science One 3:e1908,
2008: Describing a predictor for the
response to the chemotherapeutic drugs
paclitaxel, 5-fluouracil, adriamycin, and
cyclophosphamide
• Proceedings of the National
Academy of Sciences 105:19432–19437,
2008: Describing a predictor of colon
cancer recurrence
• Clinical Cancer Research 15:7553–
7561, 2009: Describing a predictor for
the response to the chemotherapeutic
drug cisplatin
As a result of Duke’s investigation, the
published papers listed above were
retracted.
Respondent has entered into a
Voluntary Settlement Agreement with
ORI. Respondent neither admits nor
denies ORI’s findings of research
misconduct; the settlement is not an
admission of liability on the part of the
Respondent. The parties entered into
the Agreement to conclude this matter
without further expenditure of time,
finances, or other resources. Respondent
has not applied for or engaged in U.S.
Public Health Service (PHS)-supported
research since 2010. Respondent stated
that he has no intention of applying for
or engaging in PHS-supported research
or otherwise working with PHS.
However, the Respondent voluntarily
agreed:
(1) That if the respondent obtains
employment in a research position in
which he receives or applies for PHS
support within five years of the effective
date of the Agreement (September 23,
2015), he shall have his research
supervised for a period of five years;
E:\FR\FM\09NON1.SGM
09NON1
]]>Agencies
[Federal Register Volume 80, Number 216 (Monday, November 9, 2015)]
[Notices]
[Page 69230]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-28436]
[[Page 69230]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
National Vaccine Injury Compensation Program: Revised Amount of
the Average Cost of a Health Insurance Policy
The Health Resources and Services Administration (HRSA) is
publishing an updated monetary amount of the average cost of a health
insurance policy as it relates to the National Vaccine Injury
Compensation Program (VICP).
Section 100.2 of the VICP's implementing regulation (42 CFR part
100) states that the revised amount of the average cost of a health
insurance policy, as determined by the Secretary of Health and Human
Services, is effective upon its delivery to the United States Court of
Federal Claims (the Court), and will be published periodically in a
notice in the Federal Register. This figure is calculated using the
most recent Medical Expenditure Panel Survey-Insurance Component (MEPS-
IC) data available as the baseline for the average monthly cost of a
health insurance policy. This baseline is adjusted by the annual
percentage increase/decrease obtained from the most recent annual
Kaiser Family Foundation and Health Research and Educational Trust
(KFF/HRET) Employer Health Benefits survey or other authoritative
source that may be more accurate or appropriate.
In 2015, MEPS-IC, available at www.meps.ahrq.gov, published the
annual 2014 average total single premium amount per enrolled employee
at private-sector establishments that provide health insurance. The
figure published was $5,832. This figure is divided by 12-months to
determine the cost per month of $486.00. The $486.00 shall be increased
or decreased by the percentage change reported by the most recent KFF/
HRET, available at www.kff.org. The percentage increase from 2014 to
2015 was published at 4 percent. By adding this percentage increase,
the calculated average monthly cost of a health insurance policy in
2015 is $505.44.
Therefore, the Secretary of Health and Human Services announces
that the revised average cost of a health insurance policy under the
VICP is $505.44 per month. In accordance with Sec. 100.2, the revised
amount was effective upon its delivery by the Secretary to the Court.
Such notice was delivered to the Court on October 23, 2015.
Dated: November 3, 2015.
James Macrae,
Acting Administrator.
[FR Doc. 2015-28436 Filed 11-6-15; 8:45 am]
BILLING CODE 4165-15-P
